The Effect of Inhaled Nitric Oxide on Pulmonary Gas-exchange in COPD

Sponsor
University of Alberta
Study ID
NCT04231760
Phase
PHASE1/PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Accepted

Interventions

  • Inhaled Nitric Oxide — DRUG
    Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.
  • Placebo — DRUG
    Inhaled placebo, which consists of breathing medical grade air (21% O2).

Study Details

Chronic Obstructive Pulmonary Disease (COPD) is a lung disorder commonly caused by smoking, which makes breathing more difficult. When COPD patients exercise, they are not efficient breathers and this leads to serious breathing difficulties, which often causes these patients to stop exercise at low intensities. Even though patients with a mild form of COPD have relatively well preserved lung function, they still have inefficient breathing during exercise. The investigators think that these individuals have problems exchanging fresh gas (i.e., oxygen) into the blood stream because of poor lung blood vessel function. The investigators will test whether inhaled medications, specifically nitric oxide, can improve lung blood vessel function and decrease breathing difficulties during exercise. With this research, the investigators will understand more about breathing efficiency and lung blood vessel function in individuals with mild COPD, and find out whether improving lung blood vessel function helps COPD patients breathe easier and exercise longer. Understanding the reasons behind the feeling of difficult breathing may lead to more effective therapy and improved quality of life in COPD patients.

Key Dates

First listed
Jan 18, 2020
Start date
Dec 1, 2026
Status verified
Jul 2026
Primary completion
Dec 1, 2027
Completion
Feb 1, 2028

Study Design

Enrollment
80 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: Chronic Obstructive Pulmonary Disease
    Mild \& Moderate COPD to receive either placebo or inhaled nitric oxide (40ppm)
  • Active Comparator: Healthy Controls
    Control group to receive either placebo or inhaled nitric oxide (40ppm)

Primary Outcome Measure

Ventilation-perfusion matching [ Time Frame: Within 20-25 minutes post-dose ]

Central Contacts

Find similar trials

Nationwide
COPD trialsPulmonology trialsLung disease trials

Related Studies